Literature DB >> 18599134

Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension.

Astrid E Lammers1, Alison A Hislop, Sheila G Haworth.   

Abstract

BACKGROUND: We aimed to assess whether levels of B-type natriuretic peptide (BNP)--an established marker of ventricular dysfunction--relate to functional status and outcome in children with idiopathic and associated pulmonary hypertension (PH). METHODS AND
RESULTS: BNP was measured in 50 children with PHT aged 8.4 +/- 5.1 years, all receiving PH specific therapies. Twenty-seven patients were diagnosed with idiopathic PH (IPAH), while 23 patients had associated PH [congenital heart disease (n = 17), lung disease (n = 4), other (n = 2)]. Functional status, six-minute walk test, echocardiographic and haemodynamic data were assessed. Mean BNP value was 143.5 +/- 236.2 pg/ml (range <5-1250). BNP correlated with Functional Class II, III, and IV (50.8 +/- 61.3, 196.9 +/- 291.2 and 280.0 +/- 276.5 respectively; p = 0.01), with echocardiographic assessment of right ventricular function (p < 0.01), hypertrophy (p < 0.01) and dilatation (p < 0.01). In IPAH BNP correlated with pulmonary arterial pressure and, on inhaled nitric oxide also with vascular resistance. During a mean follow-up of 14.0 +/- 7.5 months seven patients died, five underwent transplantation and two were listed for transplantation. Using ROC analysis, a BNP value >130 pg/ml predicted death or need for transplantation (p < 0.04). However, six children who died or were transplanted had a BNP value lower than this.
CONCLUSION: BNP correlated positively with functional status in children with pulmonary hypertension, but had limited sensitivity (57%) for predicting death or need for transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599134     DOI: 10.1016/j.ijcard.2008.03.009

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  19 in total

Review 1.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

2.  Increase in N-terminus-pro-B-type natriuretic peptide during exercise of patients with univentricular heart after a total cavopulmonary connection.

Authors:  Alfred Hager; Florian Christov; John Hess
Journal:  Pediatr Cardiol       Date:  2012-02-29       Impact factor: 1.655

Review 3.  B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.

Authors:  Chantal A Ten Kate; Dick Tibboel; Ulrike S Kraemer
Journal:  Eur J Pediatr       Date:  2015-08-23       Impact factor: 3.183

4.  Non-congenital heart disease associated pediatric pulmonary arterial hypertension.

Authors:  D D Ivy; J A Feinstein; T Humpl; E B Rosenzweig
Journal:  Prog Pediatr Cardiol       Date:  2009-12-01

Review 5.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

Review 6.  Progress in the diagnosis and management of pulmonary hypertension in children.

Authors:  Jeremy Nicolarsen; Dunbar Ivy
Journal:  Curr Opin Pediatr       Date:  2014-10       Impact factor: 2.856

7.  B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension.

Authors:  Shinichi Takatsuki; Brandie D Wagner; David Dunbar Ivy
Journal:  Congenit Heart Dis       Date:  2012-02-10       Impact factor: 2.007

Review 8.  Current developments in pediatric systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 9.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

Review 10.  Current challenges in pediatric pulmonary hypertension.

Authors:  Shinichi Takatsuki; David Dunbar Ivy
Journal:  Semin Respir Crit Care Med       Date:  2013-09-13       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.